Sildenafil, Trazodone Tablets Recalled After Being Packaged Together
AvKARE says it is not aware of any patients being harmed by the recalled products
Depression
Mortality Risk Up With Newer Antipsychotic Use for Depression
Risk up for nonelderly adults with augmentation with newer antipsychotic versus second antidepressant.
Confirmatory Testing No Longer Needed for 23andMe’s CYP2C19 Report
The 510(k) clearance allows for modification of the labeling of the previously authorized pharmacogenetics report.
Spravato Approved for MDD With Acute Suicidal Ideation or Behavior
The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.
Vitamin D3 Does Not Reduce Depression Incidence, Recurrence
Incidence and recurrence of depression, change in mood scores did not differ from placebo for adults ≥50.
Botox Injections May Ease Depression
An FDA database revealed that people who receive Botox injections report less depression.
Pre/Probiotics May Be Useful for Depression, Anxiety
All seven studies demonstrated significant improvements in one or more of the outcomes measured
Low-Dose Aspirin Does Not Prevent Depression in Older Adults
No significant difference seen in incidence rate of new CES-D-10 scores of ≥8 for aspirin, placebo
Pharmacogenetics in Antidepressant Selection for Major Depressive Disorder
Presently, clinicians should be urged to view genetics as an additional tool in choosing prescriptions for MDD, as opposed to a replacement for complete clinical evaluation.
Unapproved Cannabidiol, Curcumin Injectables Marketed for Multiple Disorders Recalled
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
